Pre-Op Nasal cream cuts staph infections by 70%?

Results. Fourteen studies described in 13 articles and a total of 1233 patients versus 1217 controls were included in the analysis. Of the 13 articles, 6 were newly published articles that had not been analysed previously and 3 were randomized controlled trials. The application of mupirocin decreased the risk by 72% [95% confidence interval (CI): 0.60–0.81] in ESI and by 70% (95% CI 0.52–0.81) in peritonitis due to S. aureus among all patients undergoing PD. Treatment of mupirocin reduced the risks of ESI and peritonitis due to all organisms by 57% (95% CI: 0.46–0.66) and 41% (95% CI: 0.24–0.54), respectively. Based on the six newly published articles, the reduced risk rate for mupirocin therapy was found to be 80% (95% CI: 0.39–0.93, P = 0.004) in ESI and 91% (95% CI: 0.72–0.97, P < 0.0001) in peritonitis due to S. aureus; 70% (95% CI: 0.47–0.82, P < 0.0001) in ESI and 42% (95% CI: 0.25–0.55, P < 0.0001) in peritonitis due to all organisms among mupirocin-treated and -untreated subjects. Based on the three randomized controlled trials, ESI and peritonitis due to S. aureus were found to be reduced by 73% (95% CI: 0.63–0.80, P < 0.0001) and 40% (95% CI: 0.17–0.56, P = 0.002), respectively. Interestingly, although mupirocin treatment can reduce the risk rate of ESI by 46% (95% CI: 0.35–0.55, P < 0.00001), it cannot decrease the risk rate of peritonitis due to all organisms (P = 0.56).

via Mupirocin for preventing exit-site infection and peritonitis in patients undergoing peritoneal dialysis — Xu et al., 10.1093/ndt/gfp411 — Nephrology Dialysis Transplantation.